Overture Orthopaedics commenced full U.S. commercial launch of OvertureTi Knee Resurfacing. The system is composed of femoral and tibial implants intended to be used in the partial replacement of the articular surfaces of the knee. These implants were designed with sizing options that allow the surgeon to replace only the diseased or damaged region of the joint while preserving healthy surrounding cartilage and meniscus. The procedure is referred to as Focalplasty.
OvertureTi Knee Resurfacing received FDA 510(k) clearance in March 2023. To date, approximately 150 cases have been successfully completed in a limited market release that commenced in November 2023.
OvertureTi implants are designed specifically as an alternative when biological repair options are not viable for treating focal cartilage lesions. The implants’ baseplates are 3D-printed, porous titanium to promote osseointegration and solid fixation. Articulating surfaces for the femoral and tibial components are titanium nitride and an over-molded, Vitamin E-treated, highly crosslinked polyethylene, respectively. They are a fraction of the cost of biological options.
“We launched our limited market release to a select number of surgeons just over 18 months ago,” shared James Young Kim, Overture’s Chief Executive Officer. “The goal was to observe early patient outcomes, refine the surgical technique, and better understand patient selection. With a good number of cases under our belt and seeing how well our patients have been doing, we are ready for the full commercial release of the OvertureTi Knee Resurfacing System. We are excited to get the product in the hands of surgeons, so that they can better address knee pain and extend active lifestyles, ultimately raising the standard of care for patients.”
Overture Orthopaedics commenced full U.S. commercial launch of OvertureTi Knee Resurfacing. The system is composed of femoral and tibial implants intended to be used in the partial replacement of the articular surfaces of the knee. These implants were designed with sizing options that allow the surgeon to replace only the diseased or damaged...
Overture Orthopaedics commenced full U.S. commercial launch of OvertureTi Knee Resurfacing. The system is composed of femoral and tibial implants intended to be used in the partial replacement of the articular surfaces of the knee. These implants were designed with sizing options that allow the surgeon to replace only the diseased or damaged region of the joint while preserving healthy surrounding cartilage and meniscus. The procedure is referred to as Focalplasty.
OvertureTi Knee Resurfacing received FDA 510(k) clearance in March 2023. To date, approximately 150 cases have been successfully completed in a limited market release that commenced in November 2023.
OvertureTi implants are designed specifically as an alternative when biological repair options are not viable for treating focal cartilage lesions. The implants’ baseplates are 3D-printed, porous titanium to promote osseointegration and solid fixation. Articulating surfaces for the femoral and tibial components are titanium nitride and an over-molded, Vitamin E-treated, highly crosslinked polyethylene, respectively. They are a fraction of the cost of biological options.
“We launched our limited market release to a select number of surgeons just over 18 months ago,” shared James Young Kim, Overture’s Chief Executive Officer. “The goal was to observe early patient outcomes, refine the surgical technique, and better understand patient selection. With a good number of cases under our belt and seeing how well our patients have been doing, we are ready for the full commercial release of the OvertureTi Knee Resurfacing System. We are excited to get the product in the hands of surgeons, so that they can better address knee pain and extend active lifestyles, ultimately raising the standard of care for patients.”
Copy to clipboard 
